ClinicalTrials.gg
RecruitingNCT06401616Updated Oct 21, 2026

Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

A Phase 4 interventional study of OAC will be discontinued for the duration of the trial in Atrial Fibrillation, Left Atrial Appendage Absent and Anticoagulant Adverse Reaction, sponsored by Odense University Hospital. Recruiting at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Odense University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 21, 2026Sponsor changed5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Atrial Fibrillation by Odense University Hospital — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Odense University Hospital.

Started
2024
the only one that year
Phase 4
Only one
of the 10
Registered
9th of 10
by date

Among the 10 studies in Atrial Fibrillation by Odense University Hospital, this one is the only one that started in 2024, is the only one in phase 4, and was the 9th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 10 studies in Atrial Fibrillation by Odense University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Atrial Fibrillation by Odense University Hospital, or all of them as a file.
02

Study summary

Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when considering the associated increased risk of bleeding. A clinical trial to address the need for anticoagulation after LAA closure is needed.

The ATLAAC trial will enroll 1220 patients with atrial fibrillation who have previously undergone surgical LAA closure. Patients will undergo a cardiac CT-scan to determine if LAA closure was successful and patients with successful closure will be randomized to continue or discontinue anticoagulation. The trial will assess the risk of ischemic stroke, peripheral arterial embolism, and major bleeding during the randomized intervention

03

Conditions studied

  • Atrial Fibrillation
  • Left Atrial Appendage Absent
  • Anticoagulant Adverse Reaction

Browse trials for

Keywords

  • Atrial fibrillation
  • Anticoagulant treatment
  • Surgical left atrial appendage closure
  • surgical left atrial appendage occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Previously undergone any type of cardiac surgical procedure including any type of surgical LAA closure (use of any of the following techniques; amputation and suture closure, stapler closure, non-amputating suture closure or closure with an approved surgical occlusion device (e.g. AtriClip)) according to the NationalPatient Register (NPR), the Danish Heart Registry (DHR) or the Western Danish Heart Registry (WDHR) from January 1st 2010 til 3 months prior to inclusion in the project.
  • Documented history of paroxysmal, persistent, or permanent atrial fibrillation or atrial flutter according to the electronic patient record

Exclusion criteria

Exclusion Criteria:

  • Not receiving OAC (warfarin/DOAC)
  • Patient specific conditions requiring OAC (e.g.mechanical valve, previous pulmonary embolism)
  • Renal impairment (estimated \< 30)
  • Allergy to contrast media
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,220 participants (estimated)

Study arms

  • Experimental
    Discontinue OAC

    OAC stopped for the duration of the trial

    Drug: OAC will be discontinued for the duration of the trial

  • No intervention
    Continue OAC

    OAC continued for the duration of the trial

Interventions

  • DrugOAC will be discontinued for the duration of the trial

    Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban

06

What researchers measure

Primary outcomes

  1. Number of participants with ischemic strokes, peripheral arterial embolisms and major bleedings

    Composite endpoint including the occurrence of ischemic stroke, peripheral arterial embolism, and major bleeding (ISTH definition)

    Time frame: After 128 primary outcome events (approx 4 years)

Secondary outcomes

  1. Severity of stroke

    According to Scandinavian Stroke Scale (0-58), lower scores mean worse outcomes

    Time frame: After 128 primary outcome events (approx 4 years)

  2. Occurence of transient ischemic attacks

    Time frame: After 128 primary outcome events (approx 4 years)

  3. Occurence of all-cause stroke

    Time frame: After 128 primary outcome events (approx 4 years)

  4. Rate of all-cause mortality

    Time frame: After 128 primary outcome events (approx 4 years)

  5. Rate of cardiovascular mortality

    Time frame: After 128 primary outcome events (approx 4 years)

  6. Occurence of minor bleeding

    All types of bleeding leading to hospital contact

    Time frame: After 128 primary outcome events (approx 4 years)

  7. Number of participants who receive blood transfusion

    Time frame: After 128 primary outcome events (approx 4 years)

  8. Occurence of myocardial infarction

    Time frame: After 128 primary outcome events (approx 4 years)

  9. Occurence of deep venous thrombosis

    Time frame: After 128 primary outcome events (approx 4 years)

  10. Occurence of pulmonary embolism

    Time frame: After 128 primary outcome events (approx 4 years)

  11. Health-related Quality of Life (HRQOL)

    EQ-5D-5L (EuroQol-5 Dimensions-5 Levels) score to evaluate generic HRQOL (0-100). Higher scores mean better quality of life.

    Time frame: Baseline (day 0) and 1 and 2 years after inclusion

  12. Patient-reported satisfaction with overall medical treatment

    Treatment Satisfaction Questionnaire (TSQM) to evaluate satisfaction related to their overall medical treatment. TSQM scoring is by domain and each domain score is computed by summing the individual TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100. Higher scores indicate higher patient satisfaction with medication.

    Time frame: Baseline (day 0) and 1 and 2 years after inclusion

  13. Patient-reported satisfaction with anticoagulant treatment

    Anti-Clot Treatment Scale (ACTS) questionnaire to evaluate satisfaction related to oral anticoagulant treatment. The ACTS Burdens total score ranges from 12 to 60, and the ACTS Benefits total score ranges from 3 to 15. Higher ACTS Burdens and Benefits scores indicate greater satisfaction with treatment.

    Time frame: Baseline (day 0) after inclusion

07

Study locations

3 of 6 sites recruiting
08

References and documents

Publications

  • Gosvig K, Goller J, Hansson NH, Brandes A, Modrau I, Rasmussen LF, Eskesen K, Jensen AKG, Belley-Cote E, Whitlock R, Riber LPS. Rationale and design of the anticoagulant therapy after left atrial appendage closure (ATLAAC) trial. Am Heart J. 2025 Sep;287:86-93. doi: 10.1016/j.ahj.2025.04.015. Epub 2025 Apr 15. PubMed 40246048 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2028, 45 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 45 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
May 7, 2024
StartActual
May 21, 2024
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (5 Denmark)
  • Rigshospitalet · Copenhagen, Denmark
  • Gentofte Hospital · Gentofte Municipality, Denmark
  • Regionshospital Gødstrup · Herning, Denmark
  • Aalborg university hospital · Aalborg, Denmark
  • Århus Universitetshospital · Aarhus, Denmark
Show 5 removed
  • Rigshospitalet · Copenhagen, Denmark
  • Gentofte Hospital · Gentofte, Denmark
  • Regionshospital Gødstrup · Herning, Denmark
  • Århus Universitetshospital · Århus, Denmark
  • Aalborg university hospital · Aalborg, Denmark
Oct 21, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40246048 ↗
Oct 21, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet·Region of Southern Denmark; collaborators removed: Rigshospitalet, Denmark·Open Patient data Explorative Network
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40246048 ↗
    5 sites added, 5 sites removed
    Show 5 added (5 Denmark)
    • Rigshospitalet · Copenhagen, Denmark
    • Gentofte Hospital · Gentofte Municipality, Denmark
    • Regionshospital Gødstrup · Herning, Denmark
    • Aalborg university hospital · Aalborg, Denmark
    • Århus Universitetshospital · Aarhus, Denmark
    Show 5 removed
    • Rigshospitalet · Copenhagen, Denmark
    • Gentofte Hospital · Gentofte, Denmark
    • Regionshospital Gødstrup · Herning, Denmark
    • Århus Universitetshospital · Århus, Denmark
    • Aalborg university hospital · Aalborg, Denmark
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet·Region of Southern Denmark; collaborators removed: Rigshospitalet, Denmark·Open Patient data Explorative Network
    + 3 other changes: verification date, date precision and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06401616
Collaborators
Copenhagen University Hospital, Rigshospitalet, Gødstrup Hospital, Aarhus University Hospital, Aalborg University Hospital, Population Health Research Institute, Region of Southern Denmark
Responsible party
Sponsor
First posted
May 7, 2024
Start date
May 21, 2024
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Kristina Gosvig, M.D.
Contact
kristina.gosvig@rsyd.dk
+4551520696
Julie Goller, M.D.
Contact
julie.goller@outlook.com
22951855
Lars Peter Riber, DMSc
principal investigator · Odense University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion